Repligen v. Centocor
Executive Summary
Repligen settles April 3 lawsuit in exchange for a share of any profits derived from the sale of a potential monoclonal antibody HIV treatment now under development by Centocor. Announced June 9, the settlement allows Centocor to continue work on its F105 antibody while acknowledging a 1987 non-compete agreement with Repligen covering HIV therapeutics, vaccines and diagnostics. That agreement gave Repligen all rights to an AIDS vaccine to which, under an earlier joint venture, Centocor had marketing rights.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth